PTPA and epilepsy: Our group has previously shown that treatment with sodium selenate in epilepsy models reduces h-tau, increases PP2A, and mitigates the development of epilepsy when delivered immediately after an epileptogenic brain injury before the occurrence of spontaneous recurrent seizures (i.e. an anti-epileptogenic effect) (Jones et al., 2012; Liu et al., 2016).